Диссертация (1140250), страница 22
Текст из файла (страница 22)
Evening -versusmorning-dosingdrugtherapyforchronickidneydiseasepatientswith hypertension: a systematic review // Kidney Blood Press Res. -2014.- Vol.39,№5.- Р.427-440.147. Lopez A. et al. Global burden of disease and risk factors / Oxford UniversityPress; 2006.148. Luyckx V.A., Naicker S., McKee M. Equity and economics of kidney diseasein sub-Saharan Africa // Lancet.- 2013.- Vol.
382.- Р. 103–104.149. Lv J., Ehteshami P., Sarnak M.J., et al. Effects of intensive blood pressurelowering on the progression of chronic kidney disease: a systematic review andmeta-analysis // CMAJ.- 2013.- Vol. 185.- Р. 949–957.150. Lv J., Neal B., Ehteshami P., et al. Effects of intensive blood pressure loweringon cardiovascular and renal outcomes: a systematic review and meta-analysis //PLoS Med.- 2012.- Vol.
9.- e1001293.151. National Kidney Foundation. K/DOQI clinical practice guidelines for chronickidney disease: evaluation, classification, and stratification // American Journal ofKidney Diseases.- 2002.- Vol.39.- 2 Suppl 1.-Р.1–266.152. National Kidney Foundation. K/DOQI. 2006 updates clinical practiceguidelinesandrecommendations.http://www.kidney.org/professionals/kdoqi/pdf/12-500210_JAG_DCP_Guidelines-HD_Oct06_SectionA_ofC.pdf153. McMurray J.J., Uno H., Jarolim P., Desai A.S., de Zeeuw D., Eckardt K.U., etal. Predictors of fatal and nonfatal cardiovascular events in patients with type 2diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial toReduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)// Am Heart J.
– 2011.- Vol. 162.- Р.748-755.e3.135154. Mahmoodi B.K. Associations of kidney disease measures with mortality andend-stage renal disease in individuals with and without hypertension: a metaanalysis. // Lancet.- 2012.- Т. 380, № 9854. С. - 1649–61155. Mann J.F., Green D., Jamerson K., et al, for the ASCEND Study Group.Avosentan for overt diabetic nephropathy// J Am Soc Nephrol.- 2010.- Vol.
21.- Р.527–535.156. Martínez-Castelao A., Górriz J.L., Bover J., Segura-de Morena J., CebolladaJ., Escalada J., et al. Consensus document for the detection and management ofchronic kidney disease // Endocrinol Nutr. – 2014.- Vol.61, №9.- e25-43157. MatsushitaK., CoreshJ., SangY., ChalmersJ., FoxC.,etal.CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuriafor prediction of cardiovascular outcomes: a collaborative meta-analysis ofindividual participant data // Lancet Diabetes Endocrinol.- 2015.- Vol.3, №7.Р.514-525.158. Matsushita K., Ballew S.H., Coresh J.
Influence of chronic kidney disease oncardiac structure and function // Curr Hypertens Rep. – 2015.- Vol.17, №9.- Р.581.159. McGaughey T.J., Fletcher E.A., Shah S.A. Impact of Antihypertensive Agentson Central Systolic Blood Pressure and Augmentation Index: A Meta-Analysis //Am J Hypertens. – 2016.- Vol.29, №4.- Р.448-457.160. Mehta R.L. и др. Refining predictive models in critically ill patients with acuterenal failure. // J. Am. Soc. Nephrol. 2002.
Т. 13. № 5. С. 1350–7.161. Mendu M.L., Waikar S.S., Rao S.K.. Kidney Disease Population HealthManagement in the Era of Accountable Care: A Conceptual Framework forOptimizing Care Across the CKD Spectrum // Am J Kidney Dis. - 2017.- pii:S0272-6386(16)30701-6.162. Mihaila V. General Population Norms for Romania using the Short Form 36Health Survey (SF-36) /V.
Mihaila, D. Enachescu, С Davila //QL News Letter. 2001. - N 26. - P. 17-18.136163. Murphy D., McCulloch C.E., Lin F., et al. Trends in prevalence of chronickidney disease in the United States // Ann Intern Med.- 2016.- Vol. 165.- Р. 473–481.164. Naimark D.M., Grams M.E., Matsushita K., Black C., Drion I., Fox C.S., InkerL.A., Ishani A., Jee S.H., et al. CKD PrognosisConsortium. Past Decline VersusCurrent eGFR and Subsequent Mortality Risk // J Am Soc Nephrol. – 2016.Vol.27, №8.- Р.
2456-2466.165. Nammas W., Koistinen J., Paana T., Karjalainen P.P. Renal sympatheticdenervation for treatment of patients with heart failure: summary of the availableevidence // Ann Med. – 2017.- Vol. 10.- Р.1-12.166. O’Seaghdha C.M., Lyass A., Massaro J.M., Meigs J.B., Coresh J., D’AgostinoR.B. et al.
A risk score for chronic kidney disease in the general population // Am JMed.-2012.- Vol.125, №3.- Р.270–277.167. Parving H.H., Brenner B.M., McMurray J.J.V, et al, for the ALTITUDEInvestigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes // NEngl J Med.- 2012.- Vol. 367.- Р. 2204–2213.168. Peeters M.J., van Zuilen A.D., van den Brand J.A., Bots M. L, Blankestijn P.J.,and Wetzels J.F. Validation of the kidney failure risk equation in European CKDpatients // Nephrol Dial Transplant.- 2013.- Vol. 28.- Р.1773–1779.169.
Perkovic V., Verdon C., Ninomiya T., et al. The relationship betweenproteinuria and coronary risk: a systematic review and meta-analysis // PLoSMed.- 2008.- Vol. 5.- e207170. Rajan M., Lai K.C., Tseng C.L., Qian S., Selim A., Kazis L., Pogach L., SinhaA. Estimating utilities for chronic kidney disease, using SF-36 and SF-12-basedmeasures: challenges in a population of veterans with diabetes // Qual Life Res.2013.- Vol.22, №1.-53-64.137171.
Raman V.K., Tsioufis C., Doumas M., Papademetriou V. Renal DenervationTherapy for Drug-Resistant Hypertension: Does It Still Work? //Curr TreatOptions Cardiovasc Med.- 2017.- Vol.19, №5.- Р.39.172. Rassa A.C., Horne B.D., McCubrey R.O., Bair T.L., Muhlestein J.B., MorrisD.R., Anderson J.L. Novel Stratification of Mortality Risk by Kidney DiseaseStage // Am J Nephrol.- 2015.- Vol. 42.- Р.443–450.173. Rucci P., Mandreoli M., Gibertoni D., Zuccalà A., Fantini M.P., Lenzi J.A clinical stratification tool for chronic kidney disease progression rate based on classificationtree analysis // Nephrol Dial Transplant.- 2014.- Vol. 3.- Р.603-610.174. Ruggenenti P., Pagano E., Tammuzzo L., Benini R., Garattini L., Remuzzi G.Ramipril prolongs life and is cost-effective in chronic proteinuric nephropathies //Kidney Int.- 2001.- Vol.59.- Р. 286–294.175. Sarafidis P.A., Georgianos P.I., Zebekakis P.E.
Comparative epidemiologyof resistant hypertension in chronic kidney disease and the general hypertensivepopulation // Semin Nephrol. – 2014.- Vol.34, №5.- Р.483-491.176. Sarnak M.J. The effect of a lower target blood pressure on the progression ofkidney disease: long-term follow-up of the modification of diet in renal diseasestudy.
// Ann. Intern. Med.- 2005. -Т. 142, № 5.- С. 342–51.177. Sharif M.U., Elsayed M.E., Stack A.G. The global nephrology workforce:emerging threats and potential solutions! // Clin Kidney J. - 2016.-Vol.9, №1.Р.11-22178. Shahinian V.B., Hedgeman E., Gillespie B.W. CDC CKD SurveillanceSystem. Estimating prevalence of CKD stages 3-5 using health system data. Am. J.Kidney Dis.- 2013.- Vol. 61.- Р. 930—938.179. Shlipak M.G., Fried L.F., Cushman M., Manolio T.A., Peterson D., StehmanBreen C., et al.
Cardiovascular mortality risk in chronic kidney disease:comparison of traditional and novel risk factors // JAMA. -2005.- Vol. 293.Р.1737-1745.138180. Sim J.J., Bhandari S.K., Shi J., Reynolds K., Calhoun D.A., Kalantar-ZadehK., Jacobsen S.J. Comparative risk of renal, cardiovascular, and mortalityoutcomes in controlled, uncontrolled resistant, and nonresistant hypertension //Kidney Int. – 2015.- Vol.88, №3.- Р.622-632.181. Smart N.A., Titus T.T.
Outcomes of early versus late nephrology referral inchronic kidney disease: a systematic review // Am. J. Med.-2011.- Vol. 124, №11.Р. 1073—1080.182. Soni R.K., Weisbord S.D., Unruh M.L. Health-related quality of life outcomesin chronic kidney disease // Curr Opin Nephrol Hypertens.
-2010.- Vol.19, №2.Р.153-159.183. Sternlicht H., Bakris G.L. The Kidney in Hypertension // Med Clin North.2017.- Vol. 101, №1.- Р. 207-217.184. Sukkar L., Hong D., Wong M.G., Badve S.V., Rogers K., Perkovic V., WalshM., Yu X., Hillis G.S., Gallagher M., Jardine M. Effects of ischaemic conditioningonmajorclinicaloutcomesinpeopleundergoinginvasiveprocedures: systematic review and meta-analysis // BMJ. -2016.- Vol. 355.Р.5599.185. Tangri N., Stevens L.A., Griffith J., Tighiouart H., Djurdjev O., Naimark D., etal. A predictive model for progression of chronic kidney disease to kidney failure //JAMA. – 2011.- Vol.305.- Р.1553-1559.186. Tangri N., Kitsios G.D., Inker L.A., Griffith J., Naimark D.M., WalkerS., RigattoC., UhligK.,LeveyA.S.Risk prediction models for patients with chronic kidney disease: a systematicreview // Ann Intern Med.
– 2013.- Vol.158, №8.- Р. 596-603.187. TangriN., GramsM.E., LeveyA.S., Coreshal. CKD Prognosis Consortium. MultinationalJ., AppelL.J., etAssessment of Accuracy ofEquations for Predicting Risk of Kidney Failure: A Meta-analysis // JAMA. –2016.- Vol.315, №2.- Р.164-174.139188. Tajima R., Kondo M., Kai H., Saito C., Okada M., Takahashi H., DoiM., Tsuruoka S., Yamagata K. Measurement of health-related quality of life inpatients with chronic kidney disease in Japan with EuroQol (EQ-5D) // Clin ExpNephrol. – 2010.- Vol.14, №4.- Р.340-348.189.
Tanner R.M,. Calhoun D.A., Bell E.K., Bowling C.B., Gutiérrez O.M., IrvinM.R., Lackland D.T., Oparil S., Warnock D,. Muntner P. Prevalence of apparenttreatment-resistant hypertension among individuals with CKD // Clin J Am SocNephrol. – 2013.- Vol.8, №9.- Р.1583-1590.190. TataruA.P., BarryA.R.ASystematicReviewofAdd-onPharmacologic Therapy in the Treatment of Resistant Hypertension // Am JCardiovasc Drugs. - 2017 Mar 27.191.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
